The MD-CARE Act, a piece of legislation designed to accelerate research and provide infrastructure needed for the development of new treatments to treat all nine forms of muscular dystrophy, has passed in the Senate by unanimous consent on September 18th. The Muscular Dystrophy Association (MDA), which has been a major advocate for passage of…
News
Recent Posts
- Health Canada speeds up its review of givinostat for Duchenne
- Collaboration is imperative to accessible design
- Experimental drug del-brax curbs signs of muscle damage in FSHD: Study
- FDA grants orphan drug, rare pediatric disease status to GEn-1123 for DMD
- Adding new adaptations around the home to allow my caregivers a break